Report Overview

The global custom antibody market was pegged at US$ 41.72 billion in 2021 and is expected to witness a CAGR of 10% during the forecast period.

Market Fundamental 

A custom antibody is made up of 90% pure antigen. Custom antibody manufacturing is used to generate both polyclonal and monoclonal antibodies. Peptide design, peptide design, animal immunisation, serum collection, titer measurement, and antibody purification are the phases in the manufacturing of custom polyclonal antibodies. Preparation of the antigen, hybridoma development immunizations, hybridoma development fusions, monoclonal manufacturing, and purification are the phases in the manufacture of a custom monoclonal antibody. Relatively speaking to the typical cultured antibodies, the custom antibody has superior selectivity. Additionally, numerous disorders, including cancer, poisoning, septicemia, viral infections, and autoimmune diseases, can be treated using custom abs. These disorders are becoming more prevalent worldwide, which helps the market. These antibodies can be used to treat patients affordably.

[8974534]

Market Dynamics 

New biomarkers are developed and discovered using custom antibody production services, which benefits the market's expansion. For the treatment of cancer and other chronic diseases, tailored medicines have also become more popular. As a result, the use of personalised antibodies is increased, spurring market expansion. GenScript introduced MonoRab, a unique rabbit mAB, in June 2021. mAB sequencing and hybridoma technologies are involved. It is more affine and offers superior specificity for a variety of applications. Growing government funding and support, improvements in biotechnology research, shifting illness profiles, and expanding public and private collaborations all contribute to market expansion.

Market Ecosystem 

The global custom antibody market has been analysed from five perspective by type, service, source, end user and region. 

Custom Antibody Market by Type

[43244324]

Based on type, the global custom antibody market has been segmented into monoclonal antibodies, polyclonal antibodies, and recombinant antibody. The monoclonal antibody dominated the segment during forecast period. One of the most effective biologics now being used for a number of purposes are monoclonal antibodies. These compounds high selectivity, specificity, and binding affinity are often what makes them useful and are mostly preferred by the researchers in all types of research studies. 

Custom Antibody Market by Services 

Based on services, the global custom antibody has been segmented intoantibody development, antibody production & purification, antibody fragmentation & labelling. The antibody development dominated the segment during forecast period. This is due to researchers putting a greater emphasis on high-quality, tailored antibodies for reproducibility. Due to the fact that validation can take too long for some early investigations, many laboratories are unable to verify the source of their antibodies. Others must take into account where to start and when to do so.

Custom Antibody Market by Source

Based on source, the global custom antibody has been segmented into rabbit and mice. The mice segment dominated the segment during forecast period. Mice are one of the most significant sources for the discovery of antibodies. They produce IgA, IgD, IgE, IgG, and IgM antibody in mice compared to the human antibody isotype subclasses, and the mice are capable of eliciting a strong immune response to a wide variety of antigen, including those extremely homologous human protein.

Custom Antibody Market by End User

 Based on end user, the global custom antibody has been segmented into pharmaceuticals & biotechnology companies, hospital & clinics, academic and research institute, contact research organisation. The pharmaceuticals and biotechnology company dominated the segment during forecast period. This is attributed to the rising need for highly specific antibodies for drug discovery and development, the expansion of genomes and proteomics research, as well as the expansion of research and development efforts in a variety of therapeutic fields.

Custom Antibody Market by Region

Based on region, the global custom antibody market has been segmented into North America, Europe, Asia Pacific and Rest of the World. North America held the greatest market share for bespoke antibodies, followed by Europe. The dominance of the North American region can be attributed to rising investments in the creation of structure-based drug designs, expanding genomics and proteomics research, rising demand for high-quality research tools for data reproducibility, growing attention to the creation of antibody-based therapeutics, and the presence of numerous international players in this region. The Asia Pacific market, on the other hand, is anticipated to experience the strongest growth during the forecast period. This is largely because of the rising investments made by governments and businesses, the expansion of biotechnology research, and the growing awareness of personalised therapeutics.

 Competitive Landscape 

Some of the prominent market players in the global custom antibody market include 

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Cell Signaling Technology Inc.
• Sino Biological, Inc.
• Rockland Immunochemicals
• BioLegend
• Creative Diagnostics
• GenScript
• Bio-Rad Laboratories Inc.
• Abcam PLC
• Agilent Technologies
• Innovagen Ab
• ProMab Biotechnologies
• Proteogenix
• Boster Biological Technology

Strategic Development 

• In June 2021, AMSBIO announced the availability of recombinant monoclonal antibody development services for rabbit and mouse. Recombinant monoclonal antibodies are created using the DimAb development platform, which is distinct from conventional hybridoma fusion techniques. It has the ability to extract IgG genes from B cells in animals who have received vaccinations. These antibodies aid in the development and commercialization of pharmaceutical goods. In October 2019, the FDA approved Beovu, a drug made from a monoclonal antibody from a rabbit. Beovu's intended use is for the treatment of wet age-related macular degeneration (AMD).
• In November 2020, Recombinant monoclonal antibody development services for rabbit and mouse were announced by AMSBIO. Based on the DimAb development platform, which differs from traditional hybridoma fusion methods, recombinant monoclonal antibodies are developed. It has the capacity to separate IgG genes from the B cells of vaccinated animals. These antibodies support the creation and market launch of pharmaceutical products. The FDA authorised Beovu, a medication developed from a rabbit monoclonal antibody, in October 2019. Wet age-related macular degeneration is what Beovu is meant to treat (AMD).
• In 2018, Market leader in the custom antibody space Abcam recently introduced two novel antibodies. These antibodies are referred to as (PBS)-only recombinant antibodies and the MKP1A07310 anti-PD-L1 antibody clone. These specialised antibodies are the result of collaboration between German industry leaders Merck KGaA and Abcam.

Frequently Asked Questions About This Report